Last updated: February 15, 2026
The drug identified by NDC 21922-0019 is Adalimumab, marketed under the brand name Humira by AbbVie. It remains one of the top revenue-generating biologics, facing increasing competition from biosimilars and newer therapies. Current market trends indicate continued revenue pressure but resilient demand in multiple therapeutic areas. Price projections suggest a gradual decline driven by biosimilar penetration, though high-volume indications and patent protections could sustain revenues in the near term.
What Is the Current Market Position of NDC 21922-0019?
Adalimumab (Humira) generated approximately $20.7 billion globally in 2022, according to IQVIA data. The US accounted for roughly 70% of sales, approximately $14.5 billion. The drug's primary indications include rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, and plaque psoriasis.
AbbVie retains exclusivity in several markets due to patent protections through 2024–2026 but faces biosimilar competition in the US and Europe. The first wave of biosimilar entries began in 2017 in Europe and 2023 in the US.
Major Competitors & Biosimilar Launches
| Biosimilar Name |
Manufacturer |
Launch Year |
Market |
Price Discount vs. Humira |
Notes |
| Amjevita |
Amgen |
2016 |
Europe |
15–25% |
First biosimilar in Europe; US launched in 2023 |
| Abrilada |
Pfizer |
2017 |
Europe |
20–30% |
Launched alongside Amjevita |
| Hyrimoz |
Sandoz |
2018 |
Europe |
20–25% |
US approval in 2023 |
| Hadlima |
Samsung Bioepis |
2019 |
Europe |
25–30% |
US approval in 2023 |
The entrance of biosimilars has already begun impacting affordability and market share, especially in Europe, where multiple biosimilars coexist.
What Is the Price Trajectory for NDC 21922-0019?
Historically, Humira's list price in the US was approximately $6,800 per month per 40 mg pen or prefilled syringe (as of 2022). This introduces an annual list price of around $81,600 per patient. Biosimilar entry is driving discounts ranging 15–30% off original list prices.
Price Projections (2023–2028):
| Year |
Estimated List Price (USD) per 40 mg pen |
Expected Discount from Original Price |
Rationale |
| 2023 |
$5,950–$6,200 |
8–12% |
Initial biosimilar launch impacts prices; limited prescribing shifts |
| 2024 |
$5,200–$5,650 |
14–20% |
Increased biosimilar competition and market volume |
| 2025 |
$4,700–$5,200 |
20–25% |
Greater biosimilar market penetration; formulary shifts |
| 2026 |
$4,200–$4,700 |
23–30% |
Patent exclusivity wanes; more biosimilar options |
| 2027 |
$3,800–$4,300 |
25–32% |
Market stabilization; generic uptake continues |
The downward trajectory assumes ongoing biosimilar adoption and managed care negotiations pressuring prices.
What Are the Pricing and Market Dynamics?
-
Pricing pressure from biosimilars: Since the US biosimilar approval in 2023, discounts of up to 30% are achievable in institutional and payer agreements.
-
Payer shifts: Payers favor biosimilars, reducing utilization of originator biologics, especially with formulary prioritization of cost-effective options.
-
Patent litigation: During 2021–2024, patent disputes limit biosimilar market share in the US, providing temporary pricing stabilization.
-
Therapeutic indications: Growing use in additional indications supports revenue continuity despite biosimilar competition.
What Factors Will Influence Future Market and Price?
- Regulatory landscape: Patent expirations in 2024–2026 result in increased biosimilar competition.
- Market adoption: Physician and patient acceptance of biosimilars influences uptake.
- Pricing strategies: AbbVie and biosimilar manufacturers may engage in negotiated price discounts and value-based agreements.
- Emerging therapies: New biologics and oral agents in indications like rheumatoid arthritis could curtail Humira's dominance.
What Are the Implications for Stakeholders?
- Investors: Expect revenue decline from original Humira over 2023–2026, offset in part by biosimilar sales.
- Manufacturers: Biosimilar entrants pressure pricing, incentivizing innovation and portfolio diversification.
- Healthcare providers: Favor biosimilars for cost savings, influencing prescribing patterns.
- Patients: Enhanced access through lowered prices, but potential limited supply of original biologics.
Key Takeaways
- NDC 21922-0019 (Humira) remains a top-selling biologic but faces increasing biosimilar competition starting 2023.
- US list prices are projected to decline by approximately 25–30% over the next five years owing to biosimilar discounting.
- The market will see a shift from original to biosimilar products, with discounts expected to range from 15% to over 30% depending on market maturity.
- Patent protections delay biosimilar saturation until 2024–2026 in many markets.
- Continued innovation and strategic pricing will be critical for maintaining revenue streams amid competitive pressure.
FAQs
1. When will biosimilars significantly impact Humira revenues?
Biosimilar competition started in the US in 2023, with market penetration increasing through 2024–2026, likely reducing original product revenues by 50% or more within this period.
2. How much can prices for Humira decline?
Average US list prices are expected to decrease 25–30% over five years, with discounts in long-term supply agreements exceeding this range in some cases.
3. Will patent expirations fully open the US market to biosimilars?
Patent expirations in 2024–2026 will enable biosimilar entry, but patent litigation and settlement strategies could delay full market access until then.
4. How does biosimilar competition affect global markets?
European markets have experienced biosimilar uptake since 2016, leading to notable price reductions. The US follows a staggered timeline beginning 2023, with similar trends expected.
5. Are there alternatives to Humira that could influence future pricing?
New biologics and oral therapies (e.g., JAK inhibitors like Rinvoq) pose competitive threats, especially in certain indications, potentially affecting overall demand and pricing strategies.
Citations
[1] IQVIA, "The Impact of Biosimilars on Market Dynamics," 2022.
[2] FDA, "Biosimilar Approvals," 2023.
[3] Abbott, "Humira Patent Expiry Timeline," 2022.
[4] EvaluatePharma, "Biologic Market Trends," 2023.
[5] CMS, "Biosimilar Reimbursement Policies," 2023.
